Samples with high BTC expression showed a significantly lower EGFR copy number (P = 8.33e−9, Wilcoxon test on median expression level TCGA-GBM) and EGFR-amplified samples showed significant downregulation of BTC in a DGE analysis in both the TCGA-GBM (LFC = −2.51, FDR-adjusted P-value = 6.74e−15) and Intellance-2 datasets (LFC = −3.07, FDR-adjusted P-value = 2.45e−08). This evidence concerns the gene BTC and glioblastoma.